MedTrace Logo

Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

NCT01090128 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-03-31

No results posted yet for this study

Summary

The purpose of this clinical trial is to test whether treatment of patients with breast cancer with the combination of Abraxane (nab-paclitaxel), Adriamycin (doxorubicin), and Cyclophosphamide prior to surgery is safe and results in good tumor response. Up to 24 patients may be enrolled in this study at the Mitchell Cancer Institute. All patients enrolling in this study will receive treatment with the combination of Abraxane, Adriamycin, and Cyclophosphamide.

Conditions

  • Stages II-III Breast Cancer

Interventions

DRUG

Nanoparticle Albumin Bound Paclitaxel

IV administered over 30 minutes. 100 mg/m2 on days 1 and 8

DRUG

doxorubicin

50 mg/m2 every 3 weeks

DRUG

cyclophosphamide

500 mg/m2 given every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Hung Khong, MD · University of Utah

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2017-03-24
Completion
2017-03-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01090128 on ClinicalTrials.gov